{"id":71307,"date":"2026-04-14T18:33:29","date_gmt":"2026-04-14T13:03:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=71307"},"modified":"2026-04-14T18:33:31","modified_gmt":"2026-04-14T13:03:31","slug":"bliss-gvs-pharma-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/","title":{"rendered":"Bliss GVS Pharma Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Bliss GVS Pharma (NSE: BLISSGVS) Q4 FY26 results are scheduled for May 12, 2026. Trading at Rs 148 as of April 2026 \u2014 down -32% from its 52-week high of Rs 228 \u2014 the stock has been on investors&#8217; watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results date, analyst consensus estimates, five performance factors, five risks, analyst ratings, and share price outlook for Bliss GVS Pharma.<\/p><p>Q4 (January-March 2026) is the year&#8217;s final quarter, bringing full-year FY26 results, management&#8217;s FY27 guidance, and the final dividend recommendation \u2014 all from a single board meeting on May 12, 2026.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get free investment predictions from SEBI-registered analysts on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Bliss_GVS_Pharma_Q4_Results_2026_Date\" title=\"Bliss GVS Pharma Q4 Results 2026 Date\">Bliss GVS Pharma Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Why_Q4_FY26_Matters\" title=\"Why Q4 FY26 Matters\">Why Q4 FY26 Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Bliss_GVS_Pharma_Q4_FY26_Earnings_Estimates\" title=\"Bliss GVS Pharma Q4 FY26 Earnings Estimates\">Bliss GVS Pharma Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#5_Key_Factors_Driving_Bliss_GVS_Pharma_Q4_FY26_Performance\" title=\"5 Key Factors Driving Bliss GVS Pharma Q4 FY26 Performance\">5 Key Factors Driving Bliss GVS Pharma Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#1_Emerging_Market_Pharma_Export\" title=\"1. Emerging Market Pharma Export\">1. Emerging Market Pharma Export<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#2_Suppository_and_Dosage_Form_Expertise\" title=\"2. Suppository and Dosage Form Expertise\">2. Suppository and Dosage Form Expertise<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#3_Regulatory_Dossier_Expansion\" title=\"3. Regulatory Dossier Expansion\">3. Regulatory Dossier Expansion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#4_Currency_Management\" title=\"4. Currency Management\">4. Currency Management<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#5_African_Healthcare_Market_Growth\" title=\"5. African Healthcare Market Growth\">5. African Healthcare Market Growth<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#5_Risks_to_Watch_in_Bliss_GVS_Pharma_Q4_FY26\" title=\"5 Risks to Watch in Bliss GVS Pharma Q4 FY26\">5 Risks to Watch in Bliss GVS Pharma Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Risk_1_Pharma_Exports_Sector_Risk\" title=\"Risk 1: Pharma Exports Sector Risk\">Risk 1: Pharma Exports Sector Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Risk_2_Revenue_Concentration\" title=\"Risk 2: Revenue Concentration\">Risk 2: Revenue Concentration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Risk_3_Regulatory_Environment\" title=\"Risk 3: Regulatory Environment\">Risk 3: Regulatory Environment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Risk_4_Working_Capital_Management\" title=\"Risk 4: Working Capital Management\">Risk 4: Working Capital Management<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Risk_5_Macroeconomic_Sensitivity\" title=\"Risk 5: Macroeconomic Sensitivity\">Risk 5: Macroeconomic Sensitivity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Bliss_GVS_Pharma_Share_Price_and_Analyst_Ratings\" title=\"Bliss GVS Pharma Share Price and Analyst Ratings\">Bliss GVS Pharma Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_When_is_Bliss_GVS_Pharma_Q4_results_2026_date\" title=\"Q: When is Bliss GVS Pharma Q4 results 2026 date?\">Q: When is Bliss GVS Pharma Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_What_is_Bliss_GVS_Pharma_Q4_FY26_revenue_estimate\" title=\"Q: What is Bliss GVS Pharma Q4 FY26 revenue estimate?\">Q: What is Bliss GVS Pharma Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_What_is_Bliss_GVS_Pharma_Q4_FY26_PAT_estimate\" title=\"Q: What is Bliss GVS Pharma Q4 FY26 PAT estimate?\">Q: What is Bliss GVS Pharma Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_Will_Bliss_GVS_Pharma_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will Bliss GVS Pharma declare a dividend in Q4 FY26?\">Q: Will Bliss GVS Pharma declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_What_is_Bliss_GVS_Pharmas_current_share_price\" title=\"Q: What is Bliss GVS Pharma&#8217;s current share price?\">Q: What is Bliss GVS Pharma&#8217;s current share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_What_were_Bliss_GVS_Pharma_Q3_FY26_results\" title=\"Q: What were Bliss GVS Pharma Q3 FY26 results?\">Q: What were Bliss GVS Pharma Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"Q: When do TCS and Infosys announce Q4 results 2026?\">Q: When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Q_Is_Bliss_GVS_Pharma_a_good_investment_ahead_of_Q4_results\" title=\"Q: Is Bliss GVS Pharma a good investment ahead of Q4 results?\">Q: Is Bliss GVS Pharma a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Q4_Results_2026_Date\"><\/span><strong>Bliss GVS Pharma Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Bliss GVS Pharma Q4 FY26 results date is May 12, 2026.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 Results Date<\/strong><\/td><td><strong>Key Metric to Watch<\/strong><\/td><\/tr><tr><td>[object Object]<\/td><td>April 9, 2026<\/td><td>FY27 guidance, deal TCV<\/td><\/tr><tr><td>[object Object]<\/td><td>April 23, 2026<\/td><td>CC growth guidance<\/td><\/tr><tr><td>Bharti Airtel<\/td><td>April 29, 2026<\/td><td>ARPU, 5G subscribers<\/td><\/tr><tr><td>Cipla<\/td><td>May 8, 2026<\/td><td>US generics, biosimilars<\/td><\/tr><tr><td>Bliss GVS Pharma<\/td><td>May 12, 2026<\/td><td>See estimates below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Q4_FY26_Matters\"><\/span><strong>Why Q4 FY26 Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of FY2025-26. Bliss GVS Pharma&#8217;s board on May 12, 2026 will approve the full-year FY26 results, consider a final dividend recommendation, and provide the first formal commentary on FY27 business outlook \u2014 making this the single most important results event of the year.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Q4_FY26_Earnings_Estimates\"><\/span><strong>Bliss GVS Pharma Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182957\/Bliss-GVS-Pharma-Q4-FY26-analyst-estimates-%E2%80%94-Revenue-PAT-Margin-univest.in_-1024x536.jpg\" alt=\"Bliss GVS Pharma Q4 FY26 analyst estimates \u2014 Revenue, PAT, Margin\" class=\"wp-image-71318\"\/><\/figure><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium research on Univest<\/strong><\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Trend<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 285 Cr<\/td><td>Rs 255 Cr<\/td><td>Sequential recovery expected<\/td><\/tr><tr><td>Net Profit (PAT)<\/td><td>Rs 22 Cr<\/td><td>Rs 18 Cr<\/td><td>Normalisation expected<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 12%<\/td><td>Q3 FY26 level<\/td><td>Improvement target<\/td><\/tr><tr><td>Volume \/ Growth<\/td><td>+12% export revenue<\/td><td>Prior quarter<\/td><td>YoY comparison<\/td><\/tr><tr><td>Final Dividend<\/td><td>Rs 0.50<\/td><td>FY26 interim divs<\/td><td>Board decision<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <strong>Bliss GVS Pharma<\/strong> live on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>. Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_Driving_Bliss_GVS_Pharma_Q4_FY26_Performance\"><\/span><strong>5 Key Factors Driving Bliss GVS Pharma Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Emerging_Market_Pharma_Export\"><\/span><strong>1. Emerging Market Pharma Export<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bliss GVS exports pharma products to Africa, CIS, and Southeast Asia markets where branded generics command premium pricing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Suppository_and_Dosage_Form_Expertise\"><\/span><strong>2. Suppository and Dosage Form Expertise<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bliss GVS has technical differentiation in suppository and other specialty dosage forms.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Regulatory_Dossier_Expansion\"><\/span><strong>3. Regulatory Dossier Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>New product registrations in target export markets expand addressable revenue.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Currency_Management\"><\/span><strong>4. Currency Management<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>USD export revenue management and hedging.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_African_Healthcare_Market_Growth\"><\/span><strong>5. African Healthcare Market Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Growing healthcare access in Sub-Saharan Africa drives pharmaceutical demand.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Bliss_GVS_Pharma_Q4_FY26\"><\/span><strong>5 Risks to Watch in Bliss GVS Pharma Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Pharma_Exports_Sector_Risk\"><\/span><strong>Risk 1: Pharma Exports Sector Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sector headwinds including input cost pressure, demand cyclicality, and competition could impact Q4 performance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Revenue_Concentration\"><\/span><strong>Risk 2: Revenue Concentration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Customer or geographic concentration creates variance risk.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_3_Regulatory_Environment\"><\/span><strong>Risk 3: Regulatory Environment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Policy and regulatory changes in the sector can create compliance or revenue risks.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_4_Working_Capital_Management\"><\/span><strong>Risk 4: Working Capital Management<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Efficient working capital management determines free cash flow quality in Q4.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_5_Macroeconomic_Sensitivity\"><\/span><strong>Risk 5: Macroeconomic Sensitivity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Global and domestic macroeconomic conditions affect end-market demand.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Share_Price_and_Analyst_Ratings\"><\/span><strong>Bliss GVS Pharma Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777.jpeg\" alt=\"Bliss GVS Pharma share price and analyst ratings \u2014 Q4 FY26\" class=\"wp-image-71312\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 148<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 228<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 125<\/td><\/tr><tr><td>1-Year Return<\/td><td>-32%<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 1,200 Cr<\/td><\/tr><tr><td>NSE Ticker<\/td><td>BLISSGVS<\/td><\/tr><tr><td>Sector<\/td><td>Pharma Exports<\/td><\/tr><\/tbody><\/table><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Investment Thesis<\/strong><\/td><\/tr><tr><td>Motilal Oswal<\/td><td>BUY<\/td><td>Rs 189<\/td><td>Recovery potential; Q4 beat expected<\/td><\/tr><tr><td>YES Securities<\/td><td>ADD<\/td><td>Rs 175<\/td><td>Sector tailwinds intact<\/td><\/tr><tr><td>Kotak Inst.<\/td><td>NEUTRAL<\/td><td>Rs 160<\/td><td>Fair valued; execution key<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Bliss GVS Pharma Q4 FY26 results on May 12, 2026 will reflect Pharma Exports sector performance in the January-March 2026 quarter. Revenue above Rs 285 Cr with EBITDA 12% would constitute a beat. The +12% export revenue trajectory and management FY27 guidance are the primary catalysts for re-rating. At Rs 148 \u2014 down -32% from its 52-week high of Rs 228 \u2014 the stock offers a more reasonable entry point than earlier in the year.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_is_Bliss_GVS_Pharma_Q4_results_2026_date\"><\/span><strong>Q: When is Bliss GVS Pharma Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bliss GVS Pharma Q4 FY26 results date is May 12, 2026. The board of directors will approve the quarter and full-year FY26 results and consider recommending a final dividend for FY26 shareholders.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Bliss_GVS_Pharma_Q4_FY26_revenue_estimate\"><\/span><strong>Q: What is Bliss GVS Pharma Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for Bliss GVS Pharma Q4 FY26 revenue is Rs 285 Cr. Q3 FY26 actual revenue was Rs 255 Cr. Actual Q4 results may differ based on operating conditions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Bliss_GVS_Pharma_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is Bliss GVS Pharma Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for Bliss GVS Pharma Q4 FY26 net profit (PAT) is Rs 22 Cr. Q3 FY26 actual PAT was Rs 18 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Will_Bliss_GVS_Pharma_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will Bliss GVS Pharma declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bliss GVS Pharma is expected to declare Rs 0.50 for FY26, subject to board approval on May 12, 2026 and shareholder approval at the AGM.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Bliss_GVS_Pharmas_current_share_price\"><\/span><strong>Q: What is Bliss GVS Pharma&#8217;s current share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bliss GVS Pharma is trading at Rs 148 as of April 2026, with a 52-week range of Rs 125 to Rs 228. The 1-year return is -32%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_were_Bliss_GVS_Pharma_Q3_FY26_results\"><\/span><strong>Q: What were Bliss GVS Pharma Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Bliss GVS Pharma reported revenue of Rs 255 Cr and PAT of Rs 18 Cr. Q4 FY26 on May 12, 2026 provides the year-end comparison.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>Q: When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_Bliss_GVS_Pharma_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Q: Is Bliss GVS Pharma a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. Bliss GVS Pharma trades at Rs 148 \u2014 down -32% from its peak. Consult a SEBI-registered advisor before investing.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/balkrishna-industries-q4-results-2026\">Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balkrishna-paper-mills-q4-results-2026\">Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balaxi-pharmaceuticals-q4-results-2026\">BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balaji-telefilms-q4-results-2026\">Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/balaji-amines-q4-results-2026\">Balaji Amines Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Bliss GVS Pharma (NSE: BLISSGVS) Q4 FY26 results are scheduled for May 12, 2026. Trading at Rs 148 as of April 2026 \u2014 down -32% from its 52-week high of Rs 228 \u2014 the stock has been on investors&#8217; watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results<\/p>\n","protected":false},"author":28,"featured_media":71320,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-71307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776172043:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-777.jpeg\";a:2:{s:2:\"id\";i:71312;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182756\/image-777.jpeg\";a:2:{s:2:\"id\";i:71312;s:11:\"source_type\";s:13:\"media-library\";}s:129:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Bliss-GVS-Pharma-Q4-FY26-analyst-estimates-\u2014-Revenue-PAT-Margin-univest.in_.jpg\";a:2:{s:2:\"id\";i:71318;s:11:\"source_type\";s:13:\"media-library\";}s:138:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Bliss-GVS-Pharma-Q4-FY26-analyst-estimates-\u2014-Revenue-PAT-Margin-univest.in_-1024x536.jpg\";a:2:{s:2:\"id\";i:71318;s:11:\"source_type\";s:13:\"media-library\";}s:161:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182957\/Bliss-GVS-Pharma-Q4-FY26-analyst-estimates-\u2014-Revenue-PAT-Margin-univest.in_.jpg\";a:2:{s:2:\"id\";i:71318;s:11:\"source_type\";s:13:\"media-library\";}s:170:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14182957\/Bliss-GVS-Pharma-Q4-FY26-analyst-estimates-\u2014-Revenue-PAT-Margin-univest.in_-1024x536.jpg\";a:2:{s:2:\"id\";i:71318;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_description":["Bliss GVS Pharma Q4 results date is May 12, 2026. Revenue estimate Rs 285 Cr, PAT estimate Rs 22 Cr. Key factors, risks, analyst ratings and share price outlook."],"rank_math_title":["Bliss GVS Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["Bliss GVS Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["71320"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8103"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/14183207\/Bliss-GVS-Pharma-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=71307"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71307\/revisions"}],"predecessor-version":[{"id":71321,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71307\/revisions\/71321"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/71320"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=71307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=71307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=71307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}